AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12839376 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (6 g/day; Group B, n = 13)
Number of subjects: 25
Study 12839376 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Group A)
Number of subjects: 25
Study 12839376 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (Group B)
Number of subjects: 25
Study 12458303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care for uninsured patients
Number of subjects: 383
Study 12458303 — intervention group
Group type: COMPARATOR
Intervention: Usual care for uninsured patients
Number of subjects: 383
Study 12458303 — intervention group
Group type: COMPARATOR
Intervention: Usual care for insured patients
Number of subjects: 383
Study 10401919 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cigarette containing 290 microg/kg body weight of tetrahydrocannabinol
Number of subjects: 60
Study 10401919 — intervention group
Group type: COMPARATOR
Intervention: Regular cigarette (placebo)
Number of subjects: 60
Study 7473798 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (0.2 mg/kg intravenous bolus followed by 0.2 mg/kg/h infusion over 6 h)
Number of subjects: 20
Study 7473798 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (equal volume physiological saline) placebo
Number of subjects: 20
Study 2075851 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear methadone detoxification procedure
Number of subjects: 0
Study 2075851 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse exponential methadone reduction curve
Number of subjects: 0
Study 2075851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose addicts
Number of subjects: 0
Study 2075851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose addicts
Number of subjects: 0
Study 7053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 150 mg
Number of subjects: 6
Study 7053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg
Number of subjects: 6
Study 7053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1500 mg
Number of subjects: 6
Study 7053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Free (unbound) ceftriaxone
Number of subjects: 6
Study 7053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Free ceftriaxone
Number of subjects: 6
Study 7053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (all doses)
Number of subjects: 6
Study 6368591 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chenodiol (750 mg/d)
Number of subjects: 916
Study 6368591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose chenodiol (375 mg/d)
Number of subjects: 916
Study 6368591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study 31690491 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise (MCE)
Number of subjects: 17
Study 31690491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIE)
Number of subjects: 17
Study 31690491 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 17
Study 30373651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 816
Study 30373651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 816
Study 30373651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study 27372525 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 182
Study 27372525 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Intervention (II)
Number of subjects: 182
Study 27372525 — intervention group
Group type: COMPARATOR
Intervention: Internal Control (IC)
Number of subjects: 182
Study 27372525 — intervention group
Group type: COMPARATOR
Intervention: External Control (EC)
Number of subjects: 182
Study 24795201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-ribavirin for 12 weeks in HCV genotype 2 infection
Number of subjects: 419
Study 24795201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-ribavirin for 24 weeks in HCV genotype 3 infection
Number of subjects: 419
Study 24795201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-ribavirin in HCV genotype 3 infection without cirrhosis
Number of subjects: 419
Study 24795201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-ribavirin in HCV genotype 3 infection with cirrhosis
Number of subjects: 419
Study 22220772 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) + Ornidazole (ORN)
Number of subjects: 58
Study 22220772 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth scaling and root planing (SRP) + Placebo
Number of subjects: 58
Study 20804443 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin (TI), single 30-U dose
Number of subjects: 36
Study 18754845 — intervention group
Group type: COMPARATOR
Intervention: Pre-HD folic acid (5 mg) administration
Number of subjects: 10
Study 18754845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-HD folic acid (5 mg) administration
Number of subjects: 10
Study 16884988 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized oxygenator with salvaged autologous blood
Number of subjects: 60
Study 16884988 — intervention group
Group type: COMPARATOR
Intervention: Nonheparinized oxygenator with cardiotomy suction
Number of subjects: 60
Study 16884988 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized oxygenator with cardiotomy suction
Number of subjects: 60
Study 16884988 — intervention group
Group type: COMPARATOR
Intervention: Nonheparinized oxygenator with salvaged autologous blood
Number of subjects: 60
Study 12876164 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term antibiotics
Number of subjects: 859
Study 12876164 — intervention group
Group type: COMPARATOR
Intervention: Surgical correction of reflux (VUR)
Number of subjects: 859
Study 12876164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (surgery and antibiotics)
Number of subjects: 859
Study 12876164 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 859
Study 12876164 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 859
Study 11054512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (base rate set at 10 bpm above average heart rate, mean 75 bpm)
Number of subjects: 27
Study 11054512 — intervention group
Group type: COMPARATOR
Intervention: Normal pacing (base rate set at 60 bpm)
Number of subjects: 27
Study 11054512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing
Number of subjects: 27
Study 11054512 — intervention group
Group type: COMPARATOR
Intervention: Normal pacing
Number of subjects: 27
Study 8723461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 298
Study 8723461 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 298
Study 1342209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine plus ranitidine (300 mg, 150 mg twice a day)
Number of subjects: 12
Study 1342209 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine plus placebo
Number of subjects: 12
Study 3859359 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + ITC (induction intrathecal chemotherapy and cranial irradiation plus maintenance ITC)
Number of subjects: 87
Study 3859359 — intervention group
Group type: COMPARATOR
Intervention: CSpRT (induction intrathecal chemotherapy and craniospinal irradiation with no maintenance ITC)
Number of subjects: 87
Study 29453300 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRAT (school-based lifestyle education involving parents)
Number of subjects: 1120
Study 29453300 — intervention group
Group type: COMPARATOR
Intervention: Usual school education (control)
Number of subjects: 1120
Study 26824884 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily hydromorphone (HOD)
Number of subjects: 37
Study 26824884 — intervention group
Group type: COMPARATOR
Intervention: Twice daily hydromorphone (HTD)
Number of subjects: 37
Study 24850606 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 79
Study 24850606 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg with UDCA
Number of subjects: 79
Study 24850606 — intervention group
Group type: EXPERIMENTAL
Intervention: combined statinotherapy with UDCA
Number of subjects: 79
Study 24850606 — intervention group
Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 79
Study 22552107 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam-based NPWT system
Number of subjects: 11
Study 22552107 — intervention group
Group type: COMPARATOR
Intervention: Gauze-based NPWT system
Number of subjects: 11
Study 20669672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) 240 mg/d added to conventional treatment for 10-14 days
Number of subjects: 35
Study 20669672 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Piperacillin, Levofloxacin, Ambroxol, Doxofylline)
Number of subjects: 35
Study 20669672 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) consisting of 18 healthy adults
Number of subjects: 35
Study 18510632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction followed by delayed tacrolimus monotherapy
Number of subjects: 131
Study 18510632 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus in combination with mycophenolate mofetil and steroids
Number of subjects: 131
Study 15787014 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-scale color maps
Number of subjects: 0
Study 15787014 — intervention group
Group type: COMPARATOR
Intervention: Human observer performance without color maps
Number of subjects: 0
Study 15787014 — intervention group
Group type: EXPERIMENTAL
Intervention: Human observer performance with color maps
Number of subjects: 0
Study 12859378 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX-A plus NASHA
Number of subjects: 38
Study 12859378 — intervention group
Group type: COMPARATOR
Intervention: NASHA alone
Number of subjects: 38
Study 11013016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroactive polyurethane dressing (Cutinova Thin)
Number of subjects: 60
Study 11013016 — intervention group
Group type: COMPARATOR
Intervention: Dry-gauze dressing
Number of subjects: 60
Study 8622603 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose bolus
Number of subjects: 8
Study 1478392 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (thrice weekly for 8 weeks, starting at 40% of maximal oxygen uptake)
Number of subjects: 20
Study 1478392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 6715100 — intervention group
Group type: EXPERIMENTAL
Intervention: Racewalking
Number of subjects: 8
Study 6715100 — intervention group
Group type: COMPARATOR
Intervention: Running
Number of subjects: 8
Study 6715100 — intervention group
Group type: EXPERIMENTAL
Intervention: Racewalking and Running at similar VO2
Number of subjects: 8
Study 29246705 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA)
Number of subjects: 0
Study 29246705 — intervention group
Group type: COMPARATOR
Intervention: Standard websites (National Cancer Institute, American Cancer Society, Breastcancer.org)
Number of subjects: 0
Study 29246705 — intervention group
Group type: COMPARATOR
Intervention: Standard websites
Number of subjects: 0
Study 29246705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DA and standard websites)
Number of subjects: 0
Study 28811107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative periarticular injection with added morphine (0.1 mg/kg)
Number of subjects: 53
Study 28811107 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative periarticular injection without added morphine
Number of subjects: 53
Study 25554555 — intervention group
Group type: EXPERIMENTAL
Intervention: 45º head-of-bed elevation
Number of subjects: 15
Study 25554555 — intervention group
Group type: COMPARATOR
Intervention: 30º head-of-bed elevation
Number of subjects: 15
Study 25554555 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeper sedation
Number of subjects: 15
Study 23646866 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 62
Study 23646866 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group with educational booklet
Number of subjects: 62
Study 21264478 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid TPAg
Number of subjects: 102
Study 21264478 — intervention group
Group type: COMPARATOR
Intervention: UBT
Number of subjects: 102
Study 21264478 — intervention group
Group type: EXPERIMENTAL
Intervention: EIA
Number of subjects: 102
Study 18793574 — intervention group
Group type: EXPERIMENTAL
Intervention: CJC-1131 (1.5 - 20.5 microg/kg) in healthy subjects
Number of subjects: 48
Study 18793574 — intervention group
Group type: EXPERIMENTAL
Intervention: CJC-1131 (1.5 - 12 microg/kg) in Type 2 diabetic patients
Number of subjects: 48
Study 18793574 — intervention group
Group type: COMPARATOR
Intervention: Placebo in healthy subjects
Number of subjects: 48
Study 18793574 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Type 2 diabetic patients
Number of subjects: 48
Study 16552507 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 253
Study 16552507 — intervention group
Group type: COMPARATOR
Intervention: Baseline ultrasound (US)
Number of subjects: 253
Study 16552507 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced computed tomography (CT)
Number of subjects: 253
Study 12590681 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, patient-interactive system
Number of subjects: 44
Study 12590681 — intervention group
Group type: COMPARATOR
Intervention: Traditional, practitioner-operated, manual programming methods
Number of subjects: 44
Study 11019764 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-sensitive multicomponent intervention with one phone call
Number of subjects: 14
Study 11019764 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-sensitive multicomponent intervention with four phone calls
Number of subjects: 14
Study 11019764 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 14
Study 11019764 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-sensitive multicomponent intervention (both one and four calls)
Number of subjects: 14
Study 8844450 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day for 16 days
Number of subjects: 12
Study 8844450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8844450 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day
Number of subjects: 12
Study 1614087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone and antibiotics (first trial)
Number of subjects: 321
Study 1614087 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics without steroids (first trial)
Number of subjects: 321
Study 1614087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone 4x daily (second trial)
Number of subjects: 321
Study 1614087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone 4x daily for 5 days, then 1x daily (second trial)
Number of subjects: 321
Study 1614087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone 1x daily (second trial)
Number of subjects: 321
Study 6486665 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 22
Study 6486665 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 22
Study 6486665 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen with fentanyl (20 or 25 micrograms/kg)
Number of subjects: 22
Study 6486665 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 30325583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate 100-mg tablets under fasting conditions
Number of subjects: 73
Study 30325583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate 100-mg tablets under fed conditions
Number of subjects: 73
Study 30325583 — intervention group
Group type: COMPARATOR
Intervention: Food intake
Number of subjects: 73
Study 29247820 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (various agents and techniques)
Number of subjects: 144
Study 29247820 — intervention group
Group type: COMPARATOR
Intervention: Different anesthetic techniques and drug subgroups
Number of subjects: 144
Study 26429522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg for 1 week
Number of subjects: 100
Study 26429522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24446723 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 0.25g
Number of subjects: 0
Study 24446723 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 0.5g
Number of subjects: 0
Study 24446723 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 1.0g
Number of subjects: 0
Study 24446723 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 2.0g
Number of subjects: 0
Study 24446723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23052890 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) with an individual target range temperature between 34 and 35 °C administered for 24 hours
Number of subjects: 1500
Study 19914974 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 121
Study 19914974 — intervention group
Group type: COMPARATOR
Intervention: H(2) antagonists
Number of subjects: 121
Study 17391558 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (6 g/d; about 2 g n-3 PUFA; 1.6 g DHA/d)
Number of subjects: 50
Study 17391558 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (walking 3 d/week for 45 min at 75% of maximum heart rate)
Number of subjects: 50
Study 17391558 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (6 g/d, placebo)
Number of subjects: 50
Study 17391558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of moderate exercise and fish-oil supplementation
Number of subjects: 50
Study 17391558 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and oil combination
Number of subjects: 50
Study 15467102 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g x d(-1) Cr + 140 g x d(-1) glucose polymer)
Number of subjects: 21
Study 15467102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15467102 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (responders with increased intramuscular Cr levels)
Number of subjects: 21
Study 11270005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil
Number of subjects: 124
Study 11270005 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/Fentanyl
Number of subjects: 124
Study 9894716 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-identical sibling BM (group A)
Number of subjects: 40
Study 9894716 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC (group B)
Number of subjects: 40
Study 8647141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 575
Study 8647141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 2253907 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine infusion after 10 mg bolus
Number of subjects: 8
Study 2253907 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine infusion alone
Number of subjects: 8
Study 2253907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 535237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hauser procedure
Number of subjects: 75
Study 535237 — intervention group
Group type: COMPARATOR
Intervention: Roux-Goldthwait procedure
Number of subjects: 75
Study 31944250 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered exercise program (10 minutes twice a day for 3 weeks)
Number of subjects: 153
Study 31944250 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered exercise program
Number of subjects: 153
Study 31944250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study 30958348 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU intranasal insulin
Number of subjects: 0
Study 30958348 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU intranasal insulin
Number of subjects: 0
Study 30958348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26795297 — intervention group
Group type: EXPERIMENTAL
Intervention: Live narrative stimuli
Number of subjects: 193
Study 26795297 — intervention group
Group type: COMPARATOR
Intervention: Audio-recorded narrative stimuli
Number of subjects: 193
Study 24393856 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer-specific peptide vaccines (RNF43, TOMM34) with uracil/tegafur (UFT) + Leucovorin (LV)
Number of subjects: 0
Study 24393856 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer-specific peptide vaccines (RNF43, TOMM34)
Number of subjects: 0
Study 24393856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines against multiple peptides (RNF43, TOMM34, FOXM1, MELK, HJURP, VEGFR1, VEGFR2)
Number of subjects: 0
Study 21765371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (500 μg/0.1 mL)
Number of subjects: 32
Study 21765371 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (4 mg/0.1 mL)
Number of subjects: 32
Study 19095404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 65
Study 19095404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) + daunorubicin
Number of subjects: 65
Study 19095404 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin only
Number of subjects: 65
Study 19095404 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil + daunorubicin
Number of subjects: 65
Study 19095404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) + verapamil + daunorubicin
Number of subjects: 65
Study 16671073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus deep brain stimulation (B‐STN DBS)
Number of subjects: 28